摘要
目的探讨术后不同放化疗时间窗及程序对高级别脑胶质瘤(HGO)疗效的影响。方法对71例术后HGG患者进行前瞻性临床研究。采用随机数字表法将其分入同步放化+辅助化疗组(RC+C组,39例)及早期化疗+同步放化+辅助化疗组(C+RC+C组,32例),比较2组患者的近期临床获益率(CBR)及无进展生存期(PFS)和总生存期fos)。结果治疗开始后5个月2组CBR差异无统计学意义(P〉0.05);8个月时,C+RC+C组CBR为87.5%,RC+C组为66.7%,差异有统计学意义(P〈0.05)。2组患者0S差异无统计学意义(P〉0.05)。C+RC+C治疗组的中位PFS为11.5月,RC+C治疗组中位PFS为8.6月,差异有统计学意义(P〈0.05)。结论术后早期替莫唑胺化疗+同步放化+辅助化疗可显著延长HGG患者PFS。
Objective To investigate effects of different times and procedures of postoperative radiation and chemotherapy on treatment efficacy of high-grade gliomas. Methods A prospective clinical trial was conducted in 71 patients with high-grade gliomas (HGG); they were separated randomly into two groups:one group including 39 patients received chemo-radiotherapy and adjuvant chemotherapy sequentially (RC+C) and the other group including 32 patients received neo-adjuvant chemotherapy and chemo-radiotherapy and adjuvant chemotherapy sequentially (C+RC+C). The clinical benefit rate (CBP), progression flee survival (PFS) and overall survival (OS) were followed up after the treatment. Results No significant difference on CBP 5 months after treatment was noted between the two groups (P〉0.05), but the CBP in the C+RC+C group (87.5%) was significantly higher than that in the RC+C group (66.7%) 8 months after treatment (P〈0.05). No significant difference on OS was noted between the two groups. The median PFS of patients in C+RC+C group was 11.5 months while that in the RC+C group was 8.6 months; the PFS of patients in C+RC+C group was significantly longer that in the RC+C group (P〈0.05). Conclusion Procedure of C+RC+C can prolong the PFS of patients with HGG.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2012年第11期1143-1147,共5页
Chinese Journal of Neuromedicine
关键词
神经胶质瘤
恶性
早期化疗
同步放化疗
总生存期
无进展生存期
Glioma
Malignancy
Neo-adjuvant chemotherapy
Concomitant chemo-radiotherapy
Overall survival
Progression flee survival